BioLingus (Cayman) Ltd (SUBL)

BioLingus (Cayman) Ltd is a pioneering Swiss biotech company recognized for its groundbreaking work in advancing oral (sublingual) and mucosal delivery of peptides and proteins. Rooted in the philosophy of being 'inspired by nature' the company employs applied bio-engineering to create innovative bio-mimetic materials for drug delivery. Focused on addressing chronic diseases such as diabetes, obesity, and inflammatory conditions, BioLingus develops its own products. The main office is situated in Switzerland, with additional branches in Hong Kong and Australia. Notably, BioLingus is at the forefront of diabetes treatment, with lead molecules including an oral 'biobetter' of liraglutide and exenatide for type II diabetes, as well as a combination product of insulin and GLP1. The company is also exploring the use of low dose IL-2 for early onset juvenile type I diabetes, demonstrating promising results in animal models. In the realm of immuno-therapy, sublingual administration facilitates direct targeting of the lymphatic system, with notable success in arthritis, psoriasis, diabetes type 1, peanut allergy, and cancer. Beyond therapeutic efficacy, BioLingus' technology offers the potential to stabilize proteins and peptides, reducing the need for a cold chain and preventing infections associated with needle handling. This innovation aligns with the company's commitment to 'broaden access' for patients in third-world countries, contributing to the World Health Organization's vital goal of expanding healthcare accessibility globally.